Effect of Waterpipe Size on Smoking Behavior and Exposures
Understanding the Effect of Waterpipe Size on Smoking Behavior, Toxicant Exposures and Subjective Experiences
1 other identifier
interventional
40
1 country
1
Brief Summary
The goal of this clinical trial is to learn how waterpipe (WP) size affects smoking behavior, toxicant exposure, and subjective experiences in young adult WP smokers (ages 21-39). The main questions it aims to answer are:
- Does WP size change puffing behavior?
- Does WP size change exposure to nicotine and carbon monoxide?
- Does WP size change perceptions of harm, satisfaction, craving, or withdrawal? Participants will smoke small, medium, and large WPs in separate sessions. Researchers will measure puffing behavior, saliva nicotine, exhaled carbon monoxide, and survey responses before and after each session.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Apr 2022
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 22, 2022
CompletedFirst Submitted
Initial submission to the registry
December 22, 2022
CompletedFirst Posted
Study publicly available on registry
January 30, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 28, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
March 30, 2024
CompletedResults Posted
Study results publicly available
November 5, 2025
CompletedNovember 5, 2025
September 1, 2025
1.9 years
December 22, 2022
June 27, 2025
October 15, 2025
Conditions
Outcome Measures
Primary Outcomes (12)
Waterpipe Evaluation Scale
An 11-item questionnaire assessing participants' subjective experience of smoking waterpipe (WP) tobacco. Each item is scored on a 7-point Likert scale (1 = "not at all" to 7 = "extremely"). For analysis, item scores were averaged across the 11 items to produce a mean WES score for each WP size, with higher scores indicating a more satisfactory smoking experience. The scale captures aspects such as satisfaction, taste, cravings, and sensory enjoyment in the throat and chest.
Immediately after the exposure (smoking)
Duke Sensory Questionnaire
A 9-item questionnaire assessing participants' sensory experience of smoking waterpipe (WP) tobacco. Each item is scored on a 7-point Likert scale (1 = "not at all" to 7 = "extremely"). Item scores were averaged across the 9 items to produce a mean DSQ score for each WP size, with higher scores indicating a more positive sensory experience (e.g., satisfaction, perceived nicotine strength, and puff intensity).
Immediately after the exposure (smoking)
Harm Perception Questionnaire
This is a 3-item scale assessing participants' perception of the harmfulness of waterpipe (WP) tobacco smoking. Each item is scored on a 7-point Likert scale ranging from 1 = "a lot less harmful" to 7 = "a lot more harmful." Item scores were averaged across the 3 items to produce a mean harm perception score for each WP size, with higher scores indicating greater perceived harm.
Immediately after the exposure (smoking)
Saliva Nicotine
How participants' nicotine concentrations change based on the different smoked waterpipe sizes
Immediately after the exposure (smoking)
Puff Topography: Smoking Time
The total time spent smoking during a single WP session, measured in minutes. Longer times indicate greater duration of smoking across WP sizes.
During the exposure (smoking), up to 45 mins
Puff Topography: Cumulative Puff Time
The total time spent actively inhaling smoke across all puffs in a WP session, measured in minutes using a puff topography device. Higher values indicate more total inhalation time.
During the exposure (smoking), up to 45 mins
Puff Topography: Puff Duration
The average length of each puff in seconds, measured using a puff topography device in the WP hose. Longer puff duration indicates deeper inhalation per puff.
During the exposure (smoking), up to 45 mins
Puff Topography: Average Flow Rate
The average rate of smoke inhaled per second during puffing, measured in liters per minute with a puff topography device. Higher flow rates indicate faster inhalation.
During the exposure (smoking), up to 45 mins
Puff Topography: Number of Puffs
The total number of puffs taken during a WP session, measured using a puff topography device. Higher counts indicate more frequent puffing.
During the exposure (smoking), up to 45 mins
Puff Topography: Total Smoke Volume Inhaled
Total smoke inhaled during a single WP session, measured in liters using a puff topography device in the WP hose. Higher values indicate greater smoke intake across WP sizes.
During the exposure (smoking), up to 45 mins
Puff Topography: Puff Volume Average
Mean volume of each puff during a WP session, measured in liters using a puff topography device in the WP hose. Higher values indicate larger puff sizes across WP sizes.
During the exposure (smoking), up to 45 mins
Puff Topography: Maximum Puff Volume
The largest single puff volume inhaled during a WP session, measured in liters using a puff topography device. Higher values indicate the strongest inhalation effort across puffs.
During the exposure (smoking), up to 45 mins
Study Arms (1)
waterpipe regular smokers
EXPERIMENTALwaterpipe regular smokers will be invited for 3 lab visits where they are allocated (random order) to smoke 3 waterpipe different sizes.
Interventions
Participants will have 3 lab visits where they are allocated (random order) to smoke a small waterpipe in one visit, smoke a medium waterpipe in a second visit and smoke a large waterpipe in a third visit.
Eligibility Criteria
You may qualify if:
- regular waterpipe smokers (smoking at least once a week for the past 6 months)
- generally healthy and
- able to provide written informed consent; and willing to attend the 3 lab sessions
You may not qualify if:
- history of chronic diseases such as diabetes, high blood cholesterol, hepatic disease
- respiratory chronic diseases
- cardiovascular diseases including low or high blood pressure (BP)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Texas at Arlington
Arlington, Texas, 76019, United States
Results Point of Contact
- Title
- Ziyad Ben Taleb
- Organization
- University of Texas at Arlington
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 22, 2022
First Posted
January 30, 2023
Study Start
April 22, 2022
Primary Completion
February 28, 2024
Study Completion
March 30, 2024
Last Updated
November 5, 2025
Results First Posted
November 5, 2025
Record last verified: 2025-09
Data Sharing
- IPD Sharing
- Will not share